Myriad Genetics (MYGN) news
Recent news
Biocon's Shaw: Biosimilars a very attractive segment
Biocon, India’s largest biopharmaceutical company, has positioned itself as a key player in the global biosimilars market, with its chairman and managing director, Kiran Mazumdar-Shaw, emphasizing the segment’s growing potential. The company recently received approval for its Glargine biosimilar in…
AInvest Wire · 1d agoMyriad Genetics and Sophia Genetics announce new collaboration to advance prostate genomic instability score technology
AInvest Wire · 6d agoMyriad Genetics, Inc.: UBS cuts target price to $3.6 from $6
AInvest Wire · Sep 9, 2026Myriad Genetics shares down 5.9% after Piper Sandler cuts to underweight from overweight
AInvest Wire · Sep 1, 2026Myriad Genetics shares down 4.3% premarket after Piper Sandler cuts to underweight from overweight
Myriad Genetics (MYRG) shares fell 4.3% in premarket trading on September 1, 2026, following an upgrade from Piper Sandler, which raised the stock to "Overweight" . The move reflects a shift in the firm’s outlook on the genetic testing and diagnostics company. Previously, Piper Sandler had…
AInvest Wire · Sep 1, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.